AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
Follow ABBV
Alert me
AbbVie Inc. 10-Q filed Aug 3, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 8, 2026: 18 added · 2 removed · 32 modified; 7 with only figures updated; 8 moved without change
-
Modified
The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of
March 31June 30, 2026 and December 31, 2025 and the results of operations for the three and six months endedMarch 31June 30, 2026 and 2025. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”